Dendritic Cell Therapy Explained

If you think of your immune system as being comprised of ‘scouts’ and ‘soldiers’ then Dendritic cells are the scouts.

They are a specialised type of white blood cell, found in the skin, lymph nodes, and most tissues of the body. Their job is to patrol for anything that looks foreign, capture pieces of it, and then travel to the lymph nodes to show those pieces to the immune system's soldier cells, the T cells.

Once the T cells have seen what to look for, they go out and attack the threat. Dendritic cells act as a bridge between innate and adaptive immunity by presenting antigens to effector immune cells, and they are widely considered the most powerful antigen-presenting cells in the body.

In healthy tissue this system works well. With cancer, two things go wrong:

1. First, cancer cells often look enough like normal cells that dendritic cells fail to flag them.
2. Second, the tumour itself can suppress local dendritic cell function, effectively muting the ‘alarm system’.

The result is that the immune system tolerates cancer cells it should be attacking. Dendritic cell therapy is an attempt to fix this directly.

The process is more involved than a typical injection, which is part of why it can only be offered by specialised centres.

It begins with a blood draw. A larger-than-usual sample is collected through a procedure called leukapheresis, which separates out the white blood cells and returns the rest to the patient. From those white cells, immature dendritic cells (or their precursors) are isolated and taken to a laboratory.

In the lab, the cells are exposed to material from the patient's specific cancer. This can be done in several ways. Some protocols use lysate, which is essentially a preparation of the patient's own tumour tissue collected during surgery or biopsy. Others use specific cancer-associated proteins. More recent approaches use what are called neoantigens, which are mutations unique to the individual patient's tumour, identified through genetic sequencing.

The dendritic cells are then matured and activated under controlled conditions. This is the "training" step. By the time they are ready to be returned to the patient, they have been exposed to the specific signatures of that patient's cancer and primed to teach the immune system to recognise it.

The trained cells are then re-infused, usually as a series of injections over several weeks or months. Schedules vary by protocol and by cancer type.

Once back in the body, the trained dendritic cells migrate to the lymph nodes and do what dendritic cells naturally do. They present what they have been taught to recognise to the T cells, prompting an immune response specifically targeted at cells displaying those cancer markers.

If the therapy works as intended, the patient's own immune system becomes capable of identifying and attacking cancer cells throughout the body, including cells in metastatic deposits or microscopic residual disease that imaging cannot detect.

This is fundamentally different from chemotherapy, which kills rapidly dividing cells indiscriminately, or radiotherapy, which targets a specific area.

Dendritic cell therapy aims to create a systemic, cancer-specific response that the immune system carries forward.

In principle, that response can continue working long after the infusions have finished. In practice, the immune system is a difficult thing to direct. The tumour microenvironment often contains signals that suppress T cell activity, and cancer cells can evolve to evade recognition. These are the reasons why dendritic cell therapy is rarely used in isolation. Combination approaches, particularly with checkpoint inhibitors, are the focus of most active research and the premise of integrative oncology.

Prostate cancer

Sipuleucel-T, sold under the brand name Provenge, is the only dendritic cell therapy currently approved by the US Food and Drug Administration (FDA). In men with metastatic castration-resistant prostate cancer who have minimal symptoms, the pivotal IMPACT trial showed a median overall survival of 25.8 months with Sipuleucel-T compared with 21.7 months with placebo, a difference of just over four months. Approved in 2010, Provenge was the first FDA-approved cellular immunotherapy. Uptake has been modest due to cost and the relatively short survival benefit, but it remains a real proof of principle for the approach.

Glioblastoma.

A phase III trial of DCVax-L, an autologous tumour-lysate-loaded dendritic cell vaccine, published in JAMA Oncology in 2023, reported a median overall survival of 19.3 months in treated patients compared with 16.5 months in an external control group, with a longer-tail survival benefit at 48 months. The trial used an externally controlled design rather than a contemporary randomised control arm, which has prompted scientific debate, but the survival signal is meaningful in a cancer where progress has been slow.

Pancreatic cancer.

More recent data from the MesoPher trial, published in 2025, showed a 2-year recurrence-free survival rate of 64% in patients with resected pancreatic cancer who received dendritic cell-based therapy after chemotherapy, compared with a historical benchmark of around 40%. The therapy has received orphan drug designation from both the FDA and the European Medicines Agency. A randomised phase 2/3 trial is planned.

Other cancers.

Active research is ongoing in renal cell carcinoma, hepatocellular carcinoma, ovarian cancer, lung cancer (particularly in combination with chemotherapy or checkpoint inhibitors), and certain blood cancers including leukaemia and multiple myeloma. The objective response rates across cancer types in dendritic cell monotherapy trials have historically rarely exceeded 15%, which is why combination strategies are increasingly the focus, especially at Verita Life’s clinic.

The pattern that emerges is consistent. Dendritic cell therapy is safe. It reliably generates an immune response. Whether that response translates into longer survival or reduced recurrence depends on the cancer type, the stage, the specific protocol, and increasingly what other treatments it is paired with.

In modern integrative oncology, dendritic cell therapy is most useful as one element of a broader treatment plan rather than as a standalone intervention. There are a few reasons for that:

Conventional therapies and immunotherapies can complement each other in ways that have become clearer in recent years. Certain chemotherapy drugs can cause cancer cells to release antigens in ways that make subsequent immune responses more effective. Radiotherapy can do something similar in a process called the abscopal effect. Combining dendritic cell therapy with anti-PD-1 checkpoint inhibitors has shown promising signals in several trials, particularly in cancers where checkpoint inhibitors alone have plateaued in effectiveness.

The other reason dendritic cell therapy fits naturally into an integrative plan is its tolerability. Most patients can receive it alongside chemotherapy, radiotherapy, or other immunotherapies without compounding side effects. It does not typically cause the immune suppression that chemotherapy does, nor the localised tissue damage that radiotherapy causes. For patients already managing the difficult side effects of conventional treatment, an immunotherapy that adds minimal additional burden is meaningful.

This is also where supportive elements of integrative oncology come in. Nutritional support, attention to gut microbiome health (which influences immune function), management of inflammation, sleep optimisation, and stress reduction all affect how well the immune system responds to any immunotherapy. The dendritic cell infusion is the most visible part of the protocol, but the conditions under which the immune system is asked to work matter too.

At our integrative oncology centre, dendritic cell therapy is offered as an adjunct to conventional cancer care, alongside nutritional support, immune-supporting therapies, and close coordination with each patient's primary oncology team. It is not positioned as a replacement for conventional treatment, and the most useful first step for any patient considering it is a conversation that includes both their treating oncologist and a clinician familiar with integrative approaches.

Compared with most cancer treatments, dendritic cell therapy has a notably mild side-effect profile. This is one of the consistent findings across thousands of patients in clinical trials.

The most common side effects are local reactions at the injection site, including redness, mild swelling, itching, or tenderness. Some patients experience flu-like symptoms in the day or two following an infusion, including low-grade fever, chills, fatigue, or muscle aches. These usually resolve on their own. Adverse events are mild and easily manageable across the published clinical trial literature.

Serious side effects, the kind classified as Grade 3 or 4 in clinical trials, are uncommon and in most studies could not be clearly attributed to the therapy itself rather than to concurrent treatments or the underlying cancer.

That said, results vary by individual. Some patients experience no noticeable side effects at all. Others experience symptoms that are more pronounced. As with any therapy, the picture depends on the patient's overall health, the specific protocol, and what other treatments are being given concurrently.

Dendritic cell therapy is one of the more promising areas of cancer immunotherapy, but it is not a finished story. The science is real, the safety profile is genuinely favourable, and the evidence base is strongest in specific settings rather than as a universal cancer treatment. For most patients, the question is not whether dendritic cell therapy is a good idea but whether it makes sense for their particular cancer, stage, and treatment plan.

If you are considering it, our doctors can talk through what the evidence looks like for your specific cancer type, how dendritic cell therapy might be sequenced with other treatments, and what realistic expectations look like.